Phase I study of glasdegib (PF‐04449913), an oral smoothened inhibitor,in Japanese patients with select hematologic malignancies期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Phase I study of glasdegib (PF‐04449913), an oral smoothened inhibitor,in Japanese patients with select hematologic malignancies

Authors:	Yosuke Minami Hironobu Minami Toshihiro Miyamoto Goichi Yoshimoto Yukio Kobayashi Wataru Munakata Yasushi Onishi Masahiro Kobayashi Geoffrey Chan Adrian Woolfson Chiho Ono Mohammed Naveed Shaik Yosuke Fujii Xianxian Zheng Tomoki Naoe

Affiliation:	1. National Cancer Center Hospital East, Kashiwa, Chiba, Japan;2. Kobe University Hospital, Kobe, Hyogo, Japan;3. Kyushu University Hospital, Fukuoka, Fukuoka, Japan;4. National Cancer Center Hospital, Chuo‐ku, Tokyo, Japan;5. Tohoku University Hospital, Sendai, Miyagi, Japan;6. Pfizer Inc, Collegeville, Pennsylvania, USA;7. Pfizer Inc, New York City, New York, USA;8. Pfizer Japan, Shibuya‐ku, Tokyo, Japan;9. Pfizer Inc, San Diego, California, USA;10. National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan

Abstract:

Keywords:	Glasdegib hedgehog signaling pathway hematologic malignancies Japanese smoothened